Table 1 Summarized overview of global innovation activities on drug development in pharmaceutical companies (July 2016 – June 2019)
All pharmaceutical companies (Number of drugs, (%)) | Top 20 leading companies (Number of drugs, (%)) | Percentage of top 20 companies | |
|---|---|---|---|
Total | 10,550 (100) | 2669 (100) | 25.3% |
Phase | |||
Discovery | 1406 (13.3) | 260 (9.7) | 18.5% |
Preclinical | 2979 (28.2) | 275 (10.3) | 9.2% |
Clinicals | 144 (1.4) | 7 (0.3) | 4.9% |
Phase I | 1794 (17) | 523 (19.6) | 29.2% |
Phase II | 1936 (18.4) | 482 (18.1) | 24.9% |
Phase III | 817 (7.7) | 230 (8.6) | 28.2% |
Pre-registration | 168 (1.6) | 46 (1.7) | 27.4% |
Registered | 146 (1.4) | 37 (1.4) | 25.3% |
Marketed | 1070 (10.1) | 754 (28.3) | 70.5% |
N/A (Technology) | 90 (0.9) | 55 (2.1) | 61.1% |
Orphan drugsa | 1076 (10.2) | 355 (13.3) | 33.0% |
Biologic productsb | 4905 (46.5) | 1165 (43.6) | 23.8% |